Innate Pharma S.A.
IPHA
$2.03
$0.021.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -12.11M | -11.23M | -13.17M | -13.58M | -13.33M |
| Total Depreciation and Amortization | 401.20K | 372.00K | 454.10K | 468.30K | 614.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.07M | 1.92M | 723.80K | 746.50K | 32.80K |
| Change in Net Operating Assets | -8.04M | -7.46M | 6.70M | 6.91M | 14.31M |
| Cash from Operations | -17.68M | -16.40M | -5.29M | -5.46M | 1.63M |
| Capital Expenditure | -32.90K | -30.50K | -57.60K | -59.40K | -152.30K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3.99M | 3.70M | 4.46M | 4.60M | 653.90K |
| Cash from Investing | 3.96M | 3.67M | 4.41M | 4.54M | 501.60K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.23M | -2.23M | -2.26M | -2.26M | -2.21M |
| Issuance of Common Stock | 7.47M | 7.47M | 1.42M | 1.42M | 46.50K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 5.94M | 5.51M | -895.90K | -924.00K | -2.33M |
| Foreign Exchange rate Adjustments | 579.90K | 537.70K | -132.20K | -136.30K | -138.30K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -500.00 | -600.00 | -- |
| Net Change in Cash | -7.20M | -6.68M | -1.92M | -1.98M | -331.50K |